Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Completed · Phase 1

Conditions studied: Pancreatic Adenocarcinoma

In brief

AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.

Key facts

Study ID
NCT00327327
Run by
AmpliMed Corporation
People needed
105
Starts
2004-02-01
Expected to finish
2009-10-01
Last updated by the study team
2010-09-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.